

Cell Division Protein FtsZ (ftsZ) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CBF53717A7D6EN.html>

Date: April 2022

Pages: 36

Price: US\$ 3,500.00 (Single User License)

ID: CBF53717A7D6EN

Abstracts

Cell Division Protein FtsZ (ftsZ) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Cell Division Protein FtsZ (ftsZ) pipeline Target constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22072TDB - Cell Division Protein FtsZ - Drugs In Development, 2022, outlays comprehensive information on the Cell Division Protein FtsZ (ftsZ) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cell Division Protein FtsZ (ftsZ) - FtsZ is a protein encoded by the ftsZ gene. It is essential cell division protein that forms a contractile ring structure at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. It recruits other cell division proteins to the septum to produce a new cell wall between the dividing cells. It binds GTP and shows GTPase activity. The molecules developed by companies in Phase I and Preclinical stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Staphylococcus aureus Infections, Tuberculosis, Acinetobacter Infections, Bacillus Infections, Bacterial Pneumonia, Enterococcus faecium Infections, Skin And Skin Structure Infections (SSSI) Caused By Bacteria, Streptococcal Pneumonia,

Vancomycin-Resistant *Enterococcus faecium* Infections and Vancomycin-Resistant *Staphylococcus aureus* (VRSA) Infections.

Furthermore, this report also reviews key players involved in Cell Division Protein FtsZ (ftsZ) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cell Division Protein FtsZ (ftsZ)

The report reviews Cell Division Protein FtsZ (ftsZ) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cell Division Protein FtsZ (ftsZ) targeted therapeutics and enlists all their major and minor projects

The report assesses Cell Division Protein FtsZ (ftsZ) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cell Division Protein FtsZ

(ftsZ) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cell Division Protein FtsZ (ftsZ)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cell Division Protein FtsZ (ftsZ) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Cell Division Protein FtsZ (ftsZ) - Overview

Cell Division Protein FtsZ (ftsZ) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cell Division Protein FtsZ (ftsZ) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cell Division Protein FtsZ (ftsZ) - Companies Involved in Therapeutics Development

Pedanium Therapeutics Ltd

TAXIS Pharmaceuticals Inc

Cell Division Protein FtsZ (ftsZ) - Drug Profiles

PED-012 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBP-17GA20 - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit ftsZ for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit FtsZ for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit FtsZ for Streptococcal Pneumonia - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit FtsZ for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

TXA-709 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cell Division Protein FtsZ (ftsZ) - Dormant Products

Cell Division Protein FtsZ (ftsZ) - Product Development Milestones

Featured News & Press Releases

Dec 13, 2019: Pedanius Therapeutics FtsZ Programme demonstrates in vivo efficacy in pneumonia caused by *Acinetobacter baumannii*

Sep 07, 2016: FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic:

Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection

Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination

Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance

Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Pedanius Therapeutics Ltd, 2022

Pipeline by TAXIS Pharmaceuticals Inc, 2022

Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Cell Division Protein FtsZ (ftsZ) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CBF53717A7D6EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CBF53717A7D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

